Introduction
The acute myelogenous leukemias (AML) are a clinically and molecularly heterogeneous set of hematopoietic disorders, in which a clone of poorly differentiated hematopoietic stem progenitor cells develops and eventually dominates normal hematopoiesis. The clonal leukemia cells contain somatically mutated genes that confer an advantage in cellular growth or survival. 1 While there have been major advances in understanding and treatment of AML, the disease is still fatal in over 70% of cases.
It has long been thought that within a given case of AML there is a hierarchy of AML cells, similar to the hierarchy of normal hematopoiesis. [2] [3] [4] In this hierarchal model, the AML cell population is maintained by a small subset of primitive leukemic 'stem' cells, and only these AML stem cells have the ability to both extensively self-renew and generate large numbers of AML cells. In contrast, the vast majority of the AML cells in a patient are not truly immortal. These leukemic 'progeny' cells may undergo limited proliferation, and often some degree of differentiation. This model predicts, for example, that current chemotherapy might produce an initial remission in the majority of patients by efficiently killing the major population of rapidly proliferating but non-immortal AML progeny cells. Nevertheless, more slowly cycling, immortal AML stem cells might be less drug-sensitive, and so would eventually expand, producing relapse in the patient. Based on this attractive model, investigation of the putative AML stem cell is critical in order to understand the development and progression of AML and to identify novel approaches for therapy.
Immunodeficient mice have been used extensively to assess the in vivo growth potential and probe the in vivo biology of human solid tumors. Several groups discovered that human AML cells engrafted and proliferated in severe combined immunodeficient (SCID) 3, [6] [7] [8] [9] mice. Subsequently, it was found that human AML cells could be transplanted successfully to the more immunodeficient non-obese diabetic (NOD)/SCID mouse strain at lower AML cell doses. 4, [10] [11] [12] Although some reports involved administration of human hematopoietic growth factors post transplant, recent results indicated that over 70% of human AML cases engrafted in NOD/SCID mice, with or without post-transplant growth factor treatment. 13 It is thought that the cells that grow and generate detectable human leukemias in this model system represent AML stem cells. 1, 2 Transplant of most cases of primary human AML cells to NOD/SCID mice resulted in bone marrow (BM) infiltration and involvement of hematopoietic organs, the primary sites of clinical AML. Transplant of AML French-American-British (FAB) classification 14 M1-type cells to immunodeficient mice resulted in extensive infiltration of the mouse BM by undifferentiated human blast cells, mirroring the clinical behavior of M1 (poorly differentiated) leukemias. 2, 13 In contrast, mice transplanted with AML M4 (monoblastic) or M5 (monocytic) cells had human leukemic cells with features of monocytemacrophages disseminated to their lungs, livers, spleens and kidneys, as is observed in patients with M4/M5 leukemias. Immunodeficient mice transplanted with M5 AML cells from some patients developed 'leukemia cutis', as seen in some patients with M5 AML. 3, 8 The BM of mice that had been transplanted with FAB M4 AML patient cells containing the Inv (16) chromosomal aberration were infiltrated with many abnormal eosinophils containing large basophilic granules, similar to the BM of the patient. 3 In addition, in some cases, mice transplanted with human leukemia cells developed central nervous system infiltration, as do some patients. 8 While the immunophenotypes of cells generated in NOD/SCID mice may, in some cases, be slightly different from those of the transplanted cells, expression of most antigens is retained. For example, transplantation of CD34
− AML cells into NOD/SCID mice resulted in CD34 +
/CD38
+ leukemia cells in the BM of recipient mice, suggesting that the injected cells underwent limited differentiation in the mice. 2, 15 In all reported cases tested, human cells recovered from transplanted immunodeficient mice contained the chromosomal abnormality demonstrated in the patient's AML cells. 8, 13 Thus, the growth of human AML cells in NOD/SCID mice appears to derive from the leukemic cell clone; the human AML cells maintain key elements of their morphology, phenotype, and genotype in the mice; and the human AML cells in the mice appear to model in vivo biology of clinical AML in humans quite well.
Recently, mutations that constitutively activate the tyrosine kinase activity of the FMS-like tyrosine kinase 3 (FLT3) receptor have been discovered in up to 40% of AML cases. These somatic mutations result in either an internal tandem duplication (ITD) of the juxtamembrane portion of this receptor or a substitution for aspartic acid 835 or isoleucine 836. 16, 17 The group of patients with these FLT3 mutations in their AML cells has an especially poor prognosis. [17] [18] [19] A previous study reported that AML cells from patients with the FLT3/ITD mutation engrafted more efficiently in NOD/SCID mice than did AML cases overall. 12, 18 We wanted to see if this would be confirmed in our AML cases, and to examine the effect of the newly discovered FLT3 point mutations.
In only a small number of cases of human AML has it been possible to develop AML cell lines that can be propagated in vitro. In contrast, over 70% of human AML cases engraft in NOD/SCID mice. 13 The growth of human AML cells in NOD/SCID mice could yield large numbers of human AML cells for direct experimental use and could also function as a renewable, potentially unlimited source of leukemia cells, via serial transplantation. This motivated us to further investigate technical and clinical-biological parameters affecting growth of human AML cells in NOD/SCID mice. To probe the potential effect of the NOD/SCID mouse environment on human AML cells, we performed comparative analyses of engraftment capacity and gene expression in human AML cells before and after transplantation to NOD/SCID mice.
Materials and methods

Patient samples
Eighteen BM or peripheral blood (PB) samples from 13 patients with AML were obtained via the Sidney Kimmel Comprehensive Cancer Center at John Hopkins hematologic malignancies cell bank. Cases were selected based on availability of sufficient numbers of cells. Five cases were selected because AML cells were available from samples obtained at the patients' relapse of AML, as well as from their initial diagnoses of AML ( For serial transplantation, cells harvested from the BM of primary transplanted mice were resuspended (2 × 10 7 cells/ml) in Hank's balanced salt solution (Gibco-BRL) containing 10% FCS and 5% rat serum (Gibco-BRL), and incubated for 15 min at 4°C. Cell preparations were depleted of mouse cells using a monoclonal antibody (MAb) kit following the manufacturer's instructions (Stem Cell Technologies). Briefly, 10 l antimouse leukocyte antibody cocktail (Stem Sep) was added per ml of cells for 15 min on ice. Cells were washed and resuspended (2 × 10 7 cells/ml), then anti-biotin tetrameric antibody complex was added (100 l complex per ml cells). After 15 min incubation at 4°C, colloidal magnetic dextran iron particle suspension was added (60 l magnetic particle susupension per ml cells) for 15 min on ice. The purified human cells were recovered after antibody-magnetic particle-coated mouse cells were removed by passage through a magnetic separation column. This human AML cell preparation (Ͼ95% human cells), immunopurified from NOD/SCID mouse BM, was then used directly for an experiment or serially transplanted to a second set of irradiated NOD/SCID mice.
Quantitation of human AML cells in NOD/SCID mice (analysis of engraftment)
Cell suspensions from transplanted mouse BM and spleens were counted (Z1 cell counter; Coulter Diagnostics, Miami, FL, USA), and viability was assessed by Trypan blue dye exclusion. To identify the human AML cells in these cell suspensions, cells were washed with ice-cold immunofluorence assay medium (IFA: pH 7.4, 0.01 M Hepes containing 0.15 M NaCl, 0.1% NaN 3 and 4% FCS) and resuspended in icecold IFA containing 2% human AB + serum to block human F c receptors. Separate aliquots of cells were stained with combinations of mouse MAbs, including anti-human CD34, CD33, HLADR, CD7, CD61, CD45, CD13 (Dako Corporation, Carpinteria, CA, USA) and rat anti-mouse CD45 (Pharmingen, San Diego, CA, USA). Additional aliquots of cells were stained with FITC-, PE-and PerCP-labeled IgG antibodies (Becton Dickinson Immunocytometry Systems, San Jose, CA, USA) as isotype controls. Cells were incubated on ice in the dark at 4°C for 30 min with MAbs, washed with IFA, resuspended in red blood cell lysis buffer (0.155 M NH 4 Cl containing 0.01 M KHCO 3 and 0.1 mM EDTA), and incubated at room temperature for 5 min. Cells were then spun (300 g, 10 min), washed with IFA, and fixed in 1% buffered formaldehyde (Sigma). Antigen expression was analyzed with a FACSort flow cyto- a Samples were obtained at initial diagnosis of AML except those indicated 'R' which were from patients with relapse. Thus, sample pairs 1 and 1R, 2 and 2R, 3 and 3R, and 4 and 4R and 5 and 5R were taken from the same patients, at initial diagnosis and at relapse.
meter equipped with an Argon laser tuned to 448 nm, using Cellquest software (Becton Dickinson). Transplanted mice were classified as engrafted with human AML cells if Ͼ1% human AML cells were detected, using FACS analysis of labeling with human leukocyte differentiation MAbs chosen to identify the immunophenotype of that AML case.
20,21
Expression of CXCR4 and engraftment
In an effort to enhance CXCR4 expression and engraftment in mice, three patient samples (cases 6, 7 and 12; chosen because large numbers of cells were available) were cultured for 48 h in IMDM containing 10% FCS, stem cell factor (SCF: 50 ng/ml), and interleukin-6 (IL6: 50 ng/ml), with or without FLT3 ligand (FL: 100 ng/ml); all three recombinant human cytokines from Peprotech (Rocky Hills, NJ, USA). AML cells from patient 6 were also cultured in serum-free medium (QBSF-60; Quality Biological, Gaithersburg, MD, USA). Expression of CXCR4 (measured using PE-conjugated MAb, Pharmingen) and capacity to engraft in NOD/SCID mice were compared, for cultured vs uncultured cells.
RT-PCR for FLT3/ITD and 835D and 836I point mutations
Total RNA was isolated using RNeasy columns (Qiagen, Valencia, CA, USA) and reverse transcribed using superscript one-step RT-PCR kits (Gibco, Gaithersburg, MD, USA). The resulting cDNA (or control lacking reverse transcriptase) was used as a template for PCR with primers R5 (5Ј-TGTCGAGCAGTACTCTAAACA-3Ј) and R6 (5Ј-ATCCTAG-TACCTTCCCAAACTC-3Ј). 16 Products were resolved on a 2.5% agarose gel. FLT3/ITD mutations were identified as bands migrating at greater than the expected 365 bp size of the wild-type FLT3. 16 To test for the FLT3 point mutation, the following primers which flank 835D and 836I were used for RT-PCR, followed by digestion with EcoRV and analysis on 1.8% agarose gels: 20F (5Ј-CTCACAGAGACCTGGCCC-3Ј) and 20R (5Ј-TTGCCCCTGACAACATAG-3Ј). 17, 22 cDNA microarrays PCR products generated from 6549 sequence verified cDNA clones were printed on to glass slides as described. 23 The arrays utilized were standard National Human Genome Research Institute microarrays consisting of 3789 sequenceverified known genes and 2778 sequence-verified expressed sequence tags [http://www.nhgri.nih.gov/DIR/microarray]. Microarrays were hybridized, scanned, and image analysis was performed as previously described. 24, 25 Briefly, fluorescently labeled cDNA was synthesized from~90 g patient leukemia RNA or~45 g cell line RNA by oligo-dT-primed polymerization in the presence of Cy3 or Cy5 fluor-dUTP respectively (Amersham Pharmacia Biotech, Piscataway, NJ, USA). Image analyses were performed using DeArray software 25 [http://www.nhgri.nih.gov/DIR/microarray]. The two fluorescent images (red and green channel) obtained constitute the raw data from which differential gene expression ratio values were calculated. All data were entered into a database using Filemaker Pro software.
Statistics
The rate of engraftment was the number of NOD/SCID mice with BM containing Ͼ1% human AML cells divided by the number of mice transplanted. The level of engraftment was the percent human AML cells in each mouse BM (or spleen). Statistical analyses of engraftment were done using SPSS version 9.0 software (SPSS, Chicago, IL, USA). Rates of engraftment in each patient sample and level of engraftment of poor prognosis vs good prognosis groups were compared by the chi square test using a significance level of 0.05. Levels of engraftment by route of infusion (i.v. vs i.p.) were compared using the non-parametric Mann-Whitney U test. Levels of engraftment by mouse organ (BM vs spleen) were compared using the Wilcoxon signed ranks test. The correlations between routes of infusion and levels of engraftment achieved were studied using the Kruskal and Wallis test 26 for multiple independent parameters. Results were expressed as median ± standard error (s.e.) of the mean with a significance level of 0.05. Levels of engraftment of AML cells, with vs without incubation with cytokines, were compared using the analysis of variance (ANOVA) test with a significance level of 0.05.
Results
Engraftment of human AML cells in NOD/SCID mice
Eighteen human AML samples (Table 1 ) from 13 different patients (including five AML cases in which samples were obtained from patients at the times of initial diagnosis of leukemia and leukemia relapse) were infused into NOD/SCID mice at a range of doses, either i.v. (n = 120 mice) or i.p. (n = 68 mice). Twelve weeks after transplant of human AML cells, mouse BM and spleens were analyzed for the presence of human AML cells by flow cytometry ( Table 2 ). The use of all three MAbs against human CD45, CD13 and CD33 was necessary to optimally detect engraftment, since the human AML cells lacked expression of one or two of these markers in some cases. Sixty-seven percent (12) of the 18 human AML samples (from 77% (10) of the 13 patients) engrafted detectably in at least one mouse (note that in cases 1R and 4, there was engraftment in only one mouse). In nine human AML samples (samples 1, 2, 4-8, 11, 13), the lowest human AML cell dose tested (10 5 cells per mouse) resulted in detectable human cell engraftment. In two samples (samples 1R, 2R), the lowest human AML cell dose tested that resulted in detectable human cell engraftment was 10 6 cells per mouse, and in one sample (sample 3), the lowest human AML cell dose tested that resulted in detectable human cell engraftment was 5 × 10 6 cells. The levels of human AML cells found in mouse BM or spleen varied from 1 to Ͼ90%. Of the 12 AML samples that resulted in engraftment, 11 AML samples generated engraftment after transplantation by the i.v. route (case 8 was transplanted only by the i.p. route). Mice transplanted i.v. had higher levels of human AML cells in BM than mice transplanted i.p. (P = 0.001). The levels of human AML cells in mouse BM were higher than in mouse spleens, whatever the route (P = 0.02). This confirmed prior reports, and subsequent studies were therefore carried out using the i.v. route for transplant of human AML cells, and only analyses of engraftment in mouse BM are presented for subsequent experiments.
Ex vivo culture of AML cells did not increase CXCR4 expression or engraftment in NOD/SCID mice
Culture of normal human placental/umbilical cord blood CD34
+ cells in the presence of SCF plus IL-6 increased their CXCR4 expression, and thereby their homing to BM and engraftment in NOD/SCID mice. 27, 28 Since FLT3 receptor is highly expressed in most AML cases, [29] [30] [31] signaling via FLT3 might augment NOD/SCID engraftment of AML cells. We tested whether 48 h culture of human AML cells in the presence of SCF plus IL-6, with or without FL, would result in enhanced CXCR4 expression or engraftment in three AML Samples were obtained at initial diagnosis of AML, except samples indicated 'R' which were taken from patients in relapse (as in Table 1 ). b The value given is the highest level of human AML cells detected in that mouse, ie best Mab combination, most heavily infiltrated tissue tested.
Leukemia
cases with large numbers of cells available (cases 6, 7 and 12; case 6 contained both the FLT3/ITD and mutated 835D, and case 7 contained a FLT3/ITD, Figure 1 ). Cultured cells had no major change in CXCR4 expression or engraftment rates/levels in any case, as compared to uncultured starting cells (data not shown).
Figure 1
Two of 13 AML patient samples expressed the FLT3/ITD and two expressed FLT3 activating point mutations. (a) Total RNA from human AML cells samples was used to amplify FLT3/ITD mRNA by RT-PCR. The amplified fragments were run on 2.5% agarose gels and visualized by ethidium bromide staining. The FLT3/ITD bands migrated above the expected 365 bp size of the wild-type FLT3 fragment. Lanes 1-13 contain patient samples 1-13. Total RNA from the EOL-1 cell line was amplified as a cell control containing the wildtype FLT3. ␤-actin levels were used as internal controls in each case, using the same RT-PCR conditions. (b) The same samples were used to amplify the exon that includes 835D and 836I by RT-PCR. The PCR products were then digested with EcoRV and analyzed in 1.8% agarose gels to assay for the presence of the point mutations.
Figure 2
AML samples from patients with poor prognostic features engrafted efficiently in NOD/SCID mice. Twelve samples obtained at initial diagnosis of leukemia were transplanted i.v. to NOD/SCID mice (10 5 cells/mouse). Each point represents the percent human AML cells in the BM of one NOD/SCID mouse. The poor prognosis group of patients had у2 of the high risk prognostic criteria (WBC Ͼ50 × 10 9 /l, CD34 у20% positive, or high risk cytogenetics). The good prognosis patients had р1 of these criteria. The levels of human AML cells in NOD/SCID mice generated by these two groups were significantly different (P Ͻ 0.002).
Patient AML cells from cases with clinical-biological features conferring poor prognosis engrafted efficiently in NOD/SCID mice
Comparison of rates of engraftment by patient AML FAB type (Tables 1 and 2 ) was done. Using only the results of mice transplanted with a single dose (10 6 ) human AML cells/mouse, higher engraftment rates (у50%) were observed in cases with the M0, M1 and M4 FAB types, and lower rates for M4eo, M5, M7 and secondary (2nd) AML cases (P = 0.0002; Chi square test). No FAB M2 or M3 cases were studied.
Six patients had white blood cell counts (WBC) Ͼ50 × 10 9 /l, a poor prognostic feature, at the initial diagnoses of their leukemias. In 10 of the cases, the AML blast cells were CD34 + , another poor prognostic characteristic. Four patients had poor prognosis cytogenetics (patients 1, 5, 10 and 13). Eight patients (patients 1, 2, 5-7, 11-13) had two of these three poor risk criteria, and four had one or none (cases 3, 4, 9, 10). We compared engraftment of the 12 samples taken at initial diagnosis and transplanted by the i.v. route as a function of the above prognostic categories (case 8 is omitted because AML cells were transplanted only by the i.p. route). Blast cells from seven of the eight patients (all but patient 12) with two poor risk criteria engrafted in mice at 10 5 cells/mouse, with a median engraftment level of 33% (range 3-94%). In the four cases with none or one poor prognostic factor, only one case engrafted in mice (case 4, which generated detectable engraftment in only one mouse) ( Table 2 , Figure 2) . The difference in the rates of engraftment by prognostic category was significant (P Ͻ 0.002; Chi square test). AML cells from five patients (patients 2, 6, 7, 10 and 11) expressed FLT3 mutations (Figure 1 ). Four of these five cases (cases 2, 6, 7 and 11) had two of the above three classical poor prognostic features; all four cases engrafted in 100% of transplanted mice at 10 5 cells/mouse (and higher doses). Of interest, these four patients had normal cytogenetics. In contrast, AML cells from patient 10, which expressed FLT3/ITD but had only one classical poor prognostic feature (poor risk cytogenetics) did not engraft. Patient 2 had a FLT3 activating point mutation at 835D and engrafted well. Patient 6 had both the FLT3/ITD mutation and a point mutation 835D (presumably at the other allele). Patients 7 and 11 expressed FLT3/ITD mutations and engrafted well.
AML cells obtained from patients at leukemia relapse did not engraft more efficiently in NOD/SCID mice than cells from the same patients at initial diagnosis
AML (stem) cells might progress and increase their virulence during the time between a given patient's initial diagnosis of leukemia and the time of leukemia relapse in that patient. 5 If so, samples from patients obtained at AML relapse might tend to engraft in NOD/SCID mice at higher rates and levels than samples obtained from the same patients at the time of their initial diagnosis of leukemia. In five of our patients, cells were available from both initial diagnosis and relapse (patients [1] [2] [3] [4] [5] . In none of these five patients tested did AML cells obtained at the patient's relapse engraft mice more efficiently than cells obtained from the same patient at initial diagnosis; in fact, the relapse samples engrafted less efficiently (Table 2) .
Human AML cells did not engraft more efficiently after passage in NOD/SCID mice
Growth of human AML cells in NOD/SCID mice might operationally 'select' for AML stem (vs progeny) cells and/or for the more virulent AML cells. If either or both were true, human AML cells obtained after passage in NOD/SCID mice might engraft more efficiently. For two of the AML cases with large numbers of cells available (cases 6 and 7), we performed primary (1st) transplants of 10 7 cells to each of 50 NOD/SCID mice (per AML case). Subsets of the transplanted mice were killed at 2-4 week intervals, and levels of human AML cells in mouse BM were determined. At 4 weeks after transplant in AML case 6, there were~10% human AML cells in the mouse BM, and these leukemias progressed to~90% human AML cells in the mouse BM at 10-14 weeks (Figure 3) . For patient 7, the levels of engraftment progressed similarly (data not shown). At 12-14 weeks, human AML cells were immunopurified from the BM of the NOD/SCID mice, and then secondarily (2nd) transplanted to a set of naive, irradiated NOD/SCID mice. After 2nd transplantation of 10 7 human AML cells, engraftment levels were not higher than after 1st transplants; in fact, the observed levels of human AML cells were lower for the 2nd than for the 1st transplant for case 6 ( Figure 3 ) and case 7 (data not shown).
Gene expression was similar in human AML cells assessed directly from the patient samples, as compared to AML cells obtained after growth in NOD/SCID mice
We performed cDNA microarray analyses on cells from two AML cases in which large numbers of cells were available (patients 6 ( Table 3 ) and 7 (similar results not shown)), before and after transplantation to NOD/SCID mice (from mice that had been transplanted in the experiment described immediately above). Approximately 6600 genes were studied using standard NHGRI microarrays [http://www.nhgri.nih.gov/DIR/microarray]. The gene expression pattern in human AML cells immunopurified from NOD/SCID BM was highly similar to that of cells directly from the patients. For example, the correlation coefficient between AML cells obtained directly from patient 6 vs AML cells immunopurified from BM of NOD/SCID mice that had been transplanted with cells from patient 6 was 0.94 (Table 3) . In patient 6, we also compared gene expression of human AML cells immunopurified from 2nd transplanted NOD/SCID mice to that of cells directly from the patient and found a correlation of 0.94 (not shown). There were a small number of genes
Figure 3
Human AML cells did not engraft more efficiently after passage in NOD/SCID mice. Fifty mice were transplanted (10 7 cells/mouse) with cells from AML patient 6. Mice were killed at time points after transplant, and the human AML cells in BM were quantified. AML cells recovered from the first set of mice at 12 weeks were then secondly transplanted to naive mice at 10 7 cells/mouse or 10 Leukemia (Ͻ5%) which differed in expression levels by two-fold or more between cells immunopurified from NOD/SCID BM and cells directly from the patient in the individual experiments. For example, in the primary transplant from patient 6, there were 21 genes increased Ͼ3-fold relative to the direct patient sample (Table 3 ). However, only three genes were increased or decreased by three-fold or more, consistently in all three of the hybridization comparisons done. Cathepsin G (CTSG), a neutrophil protease, was up-regulated Ͼ10-fold in all three hybridizations. Expression of the genes for the inter-alpha trypsin inhibitor, H1 polypeptide (ITIH1) and anion exchanger, member 2 (SLC4A2), were also up-regulated in all three hybridizations (Ͼ5-fold and Ͼ3-fold, respectively). Only five genes were consistently reduced in expression in AML cells immunopurified from NOD/SCID BM relative to cells directly from the patient in all three experiments. These were CD16 (Ͻ6-fold), chaperonin containing TCP1, subunit 5 (CCT5) (Ͻ3-fold), H1 histone family, member 2 (H1F2) (Ͻ3-fold), and CD38 (Ͻ3-fold).
Discussion
In the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins hematologic malignancies cell bank, only about half of the AML samples have Ͼ10 8 cells available. In very few cases are there samples from patients both at initial diagnosis and at relapse, as relapse may not be suspected clinically before the patient's BM aspiration is performed. In addition, the AML cells often comprise only a minority of the BM sample at relapse. Many investigations of cancer cell biology require large numbers of patient cells, at both diagnosis and relapse. If AML studies utilize solely cases with large numbers of cells available, we will be investigating only a subset of cases, which may introduce a case selection bias. For example, it is conceivable that the cases with larger numbers of cells available may tend to be the more proliferative cases of AML. Several studies have demonstrated that leukemia cells from many cases of human AML engraft and proliferate in immunodeficient mice. [2] [3] [4] [6] [7] [8] [9] [10] [11] [12] [13] [14] Whereas there are relatively few AML cell lines available, the growth of human AML cells in NOD/SCID mice from over 70% of AML patients could yield large numbers of human AML cells for immediate use and a renewable, potentially unlimited source of leukemia cells via serial transplantation.
Most previous studies have investigated rates of engraftment after i.v. infusion of a relatively high dose of human AML cells to NOD/SCID mice (usually 10 7 AML cells/mouse). If small numbers of AML cells could engraft and proliferate in NOD/SCID mice, this might be quite useful for the purpose of expanding the availability of human AML cells. Therefore, we titered down the AML cell dose per mouse and found that most AML cases that engrafted after transplant of 10 7 AML cells/mouse also engrafted at doses as low as 10 5 AML cells/mouse. In over 90% of patients diagnosed with AML, 10 5 AML cells should be available for expansion in NOD/SCID mice, since 10 6 cells are needed for minimal immunophenotyping (immunophenotyping is successfully accomplished in Ͼ90% of cases; unpublished results). A caveat is that the Ͼ70% reported NOD/SCID engraftment rate 13 (confirmed by our results herein) for AML may represent an overestimation, because case selection may be biased toward cases with larger cell numbers available.
Our results confirm that the i.v. route generally results in higher levels of engraftment, especially in BM, than the i.p. route. Nevertheless, we have also observed (unpublished results) that some lymphoid leukemia/lymphoma cells that have a propensity to engraft and proliferate in lymphoid organs, such as spleen and thymus, engraft very efficiently after i.p. transplantation. It is possible that this is also true for some cases of AML, and case selection may explain the results of two studies 8, 9 that found higher engraftment after transplantation by the i.p. route.
We also confirmed that clinical-biological prognostic features of AML cases affected NOD/SCID engraftment. Previous studies 13, 18 showed that AML cells from patients with high initial WBC or poor risk chromosomal rearrangements had higher rates of engraftment than did AML cells from patients with better prognostic features. Our results confirm that AML cells from patients with poor prognostic features, 12, 13 including cases with Ͼ20% CD34
+ cells, have a higher likelihood of engraftment in NOD/SCID mice than do AML cells from cases with better prognostic features. Expression of the FLT3/ITD mutation is a new prognostic factor, and AML cases with this mutation, which activates the FLT3 receptor tyrosine kinase, engrafted efficiently in NOD/SCID mice. 18 Recently, AML cases with kinase-activating point mutations in FLT3 have been described. 17 Our results confirm that the subset of AML cases with kinase-activating FLT3 mutations (including point mutations and the FLT3/ITD mutation) were highly likely to engraft at high levels in NOD/SCID mice at low transplanted cell doses. FLT3 activation in AML cells, by whatever mechanism, may confer high virulence.
Since AML cells from poor prognosis patients appear to engraft more efficiently than cells from patients with better prognostic features, AML cells obtained from patients at relapse might be expected to engraft more efficiently than cells obtained at initial diagnosis. 32 Previous studies showed that samples from patients at relapse engrafted efficiently in general, but there were no comparisons of cells obtained from the same patients, at initial diagnosis vs at relapse. 13 Our paired samples (obtained at initial diagnosis of AML vs AML relapse) from five patients did not show increased engraftment by the relapse samples (in fact the level of engraftment appeared to be lower, for unknown reasons). It will be interesting to correlate the biology of leukemia relapse with comparative gene expression results in similar sets of paired patient samples. Perhaps, for example, these five patients relapsed because of drug resistance or failure of immune rejection, factors which would not be expected to alter their engraftment or proliferation in NOD/SCID mice.
The engraftment capacity of AML cells did not increase detectably after one to two passages in mice. This suggests that progression to increased virulence may be a slow process. 33 Of practical importance, this indicates that AML cells expanded by serial passage in NOD/SCID mice are similar in their in vivo growth potential to cells obtained directly from the patient. Thus, the growth of human AML cells in NOD/SCID mice could yield large numbers of human AML cells for immediate use and a renewable, potentially unlimited source of leukemia cells via serial transplantation of AML cells. In Ͻ1% of AML cases has it been possible to derive cell lines from the leukemia cells, and it is not known how well these cell lines represent the leukemia cells originally obtained from the patient. In contrast, over 70% of AML cases engraft in NOD/SCID mice. The cells obtained from NOD/SCID mice do not appear to be more virulent than those obtained directly from the patient, although further biological assays are necessary to confirm that the AML cells remain biologically stable during repeated passage.
Gene expression profiling of AML cells from two patients that had been passaged in NOD/SCID mice vs AML cells obtained directly from the patients suggests that AML cells cultivated in NOD/SCID mice faithfully reproduced the expression levels of the vast majority of genes, as compared to original leukemia. Furthermore, faithful expression was retained in the 2nd transplant from patient 6. On the other hand, the genes whose expression is changed after growth in NOD/SCID mice may affect the phenotype or biology of the transplanted leukemias. The few genes which were expressed at higher levels in AML cells obtained from NOD/SCID mice included genes associated with granulocytic differentiation such as cathepsin G, myeloperoxidase, defensin alpha, and secretory granule proteoglycan 1. This may be consistent with the observation that AML stem cells differentiate to some extent in NOD/SCID mice. In the future, correlated observations of the effects of pathophysiological genetic changes common in AML (eg FLT3 mutation) on growth in NOD/SCID mice and gene expression by microarray analysis could be used to develop and test new therapeutic approaches.
